abstract |
OX40 is a powerful immunostimulatory target. A method of treating cancer, comprising administering to a subject in need thereof an OX40 agonist and a common γ chain (γc) cytokine or fragment, variant, analog, or derivative thereof having activity provide. In certain aspects, the common γ chain (γc) cytokine is interleukin-2 (IL-2) or an active fragment, variant, analog, or derivative thereof. Combination treatment with the agonist anti-OX40 mAb and IL-2 synergized to enhance tumor immunotherapy for a number of tumor types. Dual therapy could also restore anergic tumor reactive CD8 + T cell function. |